Largest CIDP Trial Offers Promising Results for Drug Combo Largest CIDP Trial Offers Promising Results for Drug Combo
Nearly 70% of patients showed improvement after treatment with efgartigimod plus rHuPH20 in phase 2 of the largest randomized controlled trial for CIDP to date.MDedge News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 25, 2024 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Takeda ’s Gammagard Liquid Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
New Indication Delivers on Takeda’s Commitment to Expanding its Broad and Diverse Immunoglobulin (IG) Portfolio to Meet the Needs of People Living with CIDP
Approval Supported by Phase 3 ADVANCE-CIDP Open-label Study Data Demonstrating... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 29, 2024 Category: Drugs & Pharmacology Source Type: news
FDA OKs Subcutaneous Therapy for CIDP FDA OKs Subcutaneous Therapy for CIDP
HyQvia, which combines immunoglobulin with hyaluronidase, is administered subcutaneously by a healthcare professional or the patient or caregiver, after appropriate training.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 17, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
U.S. FDA Approves Takeda ’s Hyqvia as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Hyqvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous Immunoglobulin (SCIG) Infusion to Treat CIDP, Can Be Administered by a Healthcare Professional or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 16, 2024 Category: Drugs & Pharmacology Source Type: news
First Treatment in 30 Years for Rare Disease Safe, Effective First Treatment in 30 Years for Rare Disease Safe, Effective
Subcutaneous efgartigimod PH20 SC is effective and tolerable for the treatment of CIDP, providing a convenient alternative to intravenous and other older treatments.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 6, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Efgartigimod Offers Hope in Chronic Inflammatory Demyelinating Polyneuropathy
(MedPage Today) -- PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial.
Patients with diagnosed chronic inflammatory... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - November 5, 2023 Category: Neurology Source Type: news
Novel C1s Inhibitor Shows Promising Activity in Rare Neurologic Disorder
(MedPage Today) -- PHOENIX -- The investigational agent riliprubart, a complement C1s inhibitor, showed encouraging activity in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), according to a phase II proof-of-concept study... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - November 3, 2023 Category: Neurology Source Type: news
Immunovant Doubles — And Slugs Argenx
said Tuesday its drug lowered a key antibody in healthy people, signaling it could treat a myriad autoimmune conditions, and IMVT stock launched to a two-year high. The company tested its drug, known as IMVT-1402, in healthy adults. The experimental under-the-skin shot led to dose-dependent…#imvt1402 #albumin #immunovant #igg #leerinkpartners #thomassmith #argenx #argx #vyvgart #cidp (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2023 Category: Consumer Health News Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
SPRING HOUSE, PENNSYLVANIA, February 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition which can cause life-threatening anemia in the fetus. It occurs when the blood types of a pregnant individual and their fetus are incompatible.1 The trial met the primary endpoint, with the majority of pregnant patients who received nipocalimab achieving a live b...
Source: Johnson and Johnson - February 8, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data on Diagnosing Demyelinating Polyradiculoneuropathy New Data on Diagnosing Demyelinating Polyradiculoneuropathy
There is a potential role for the lymphocyte to monocyte ratio as a predictive and prognostic biomarker for CIDP.First Look (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 1, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa., Dec. 9, 2019 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader CSL Behring ann... Biopharmaceuticals, Neurology, FDA CSL Behring, HIZENTRA, Immune Globulin, Demyelinating Polyn (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 9, 2019 Category: Pharmaceuticals Source Type: news
5 Things to Know About CIDP 5 Things to Know About CIDP
While a rare, often perplexing disease, chronic inflammatory demyelinating polyneuropathy is a treatable condition.Medscape Neurology (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2019 Category: Infectious Diseases Tags: Neurology & Neurosurgery Article Source Type: news
What is the Recurrence Rate for Guillian-Barr é Syndrome and Should She Get An Influenza Vaccine?
Discussion
Guillian-Barré syndrome (GBS) is an acquired, acute, inflammatory, demyelinating polyneuropathy. It is the most common cause of acute and subacute flaccid paralysis in children. GBS causes about 0.4-1.3 cases per 100,000 persons/year in children. It can occur in any age group and the incidence increases among all age groups until a peak in the 50s. Both genders are affected and there may be a slight increase in males.
GBS usually occurs 2-4 weeks after a prodromal gastroenteritis or respiratory illness. GBS causes autoantibody production against Schwann cells of the neuron and the axon itself. There is ...
Source: PediatricEducation.org - November 19, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
